2 Minute Medicine: Pharma Roundup – Geopolitical instability in the Strait of Hormuz threatens global generic drug supply, daraxonrasib improves pancreatic cancer survival, sparsentan (Filspari) approved for focal segmental glomerulosclerosis, glucagon-like peptide-1 receptor agonists linked to reduced substance use disorders, and orforglipron (Foundayo) expands oral weight loss therapy options

Ongoing escalations in the Strait of Hormuz have triggered a sharp drop in maritime shipping through the region, putting pressure on the global pharmaceutical supply chain. While the corridor is best known as a petroleum chokepoint, the United States Pharmacopeia (USP) warned on April 7, 2026, that it also remains a critical transit hub for active pharmaceutical ingredients and finished generics. Disruptions are already affecting regional production and shipment flows, with delays touching commonly used products such as amoxicillin oral suspension and flumazenil API. According to supply chain analysts, the conflict has also reduced air cargo capacity, raising concern for cold chain biologics and insulin. This kind of disruption can travel farther and faster than it first appears. Some products will likely feel the pressure sooner than others depending on inventory depth. A further tightening of shipping routes, as outlined by Think Global Health, could make shortages and pricing pressure more visible in the U.S. by early May.

Revolution’s daraxonrasib demonstrates unprecedented survival in pancreatic cancer
Revolution Medicines announced positive topline results from the Phase 3 RASolute 302 trial on April 13, 2026, showing that daraxonrasib nearly doubled survival in previously treated metastatic pancreatic cancer. In the intent to treat population, the RAS(ON) multi selective inhibitor delivered a median overall survival of 13.2 months compared with 6.7 months for standard chemotherapy. Updated data presented at the AACR Annual Meeting on April 21 also showed a strong objective response rate when used in combination therapy. These results stand out in a disease where progress has historically been limited. The consistency of the benefit across groups has also drawn attention. The company plans to submit these findings to the FDA. Experts at Dana Farber have described this as a meaningful advance for a population with limited treatment options.

FDA grants full approval to sparsentan (Filspari) as first ever treatment for focal segmental glomerulosclerosis (FSGS)
The FDA granted full approval to sparsentan (Filspari) on April 13, 2026, for the reduction of proteinuria in adult and pediatric patients with focal segmental glomerulosclerosis. As the first approved therapy specifically for this rare kidney disease, it represents a major shift in treatment. Phase 3 DUPLEX study data showed rapid and sustained reductions in proteinuria compared with irbesartan. This aligns with the broader move toward disease specific treatment strategies. The expanded FDA indication includes patients aged 8 and older without nephrotic syndrome. Common adverse reactions include peripheral edema, hypotension, and hyperkalemia. Long term outcomes will be important to monitor as use expands.

Glucagon-like peptide-1 (GLP-1) receptor agonists linked to reduced risk of substance use disorders
A large cohort study of more than 600,000 U.S. veterans suggests that glucagon-like peptide-1 (GLP-1) receptor agonists may reduce cravings across multiple addictive substances. Use of these medications was associated with a lower risk of developing new substance use disorders compared with sodium-glucose cotransporter-2 inhibitors. Risk reductions were observed across opioids, nicotine, and cocaine. The findings add to growing evidence that these drugs may influence reward pathways in the brain. Patients often report reduced cravings beyond food, which may reflect this mechanism. The WashU Medicine report also noted fewer overdoses among those with pre existing conditions. A BMJ study provides additional context for these findings. More research will be needed to confirm whether these medications can be used directly in addiction treatment.

Lilly’s orforglipron (Foundayo) launches with no food restrictions
The FDA has approved orforglipron (Foundayo), the first non peptide oral glucagon-like peptide-1 (GLP-1) receptor agonist for chronic weight management. Approved on April 1, 2026, and available through LillyDirect, the tablet can be taken without food or water restrictions. Clinical trials showed an average weight loss of 12.4% at the highest dose. This flexibility may make treatment easier for many patients compared with injectable options. It also removes one of the more inconvenient dosing requirements seen with earlier oral therapies. The FDA accelerated decision made this one of the fastest approvals in recent years. Real world adoption will likely depend on cost, access, and tolerability.

Image: PD